ImmuPharma PLC: Encouraging Final Phase IIb Results Seen with LUPUZOR(TM) in Systemic Lupus Erythematosus
Greatest Benefits Seen in Patients with Moderate to Severe Systemic Lupus Erythematosus
Thursday, November 19, 2009
LONDON, Nov 19, 2009 (BUSINESS WIRE) -- ImmuPharma PLC (LSE:IMM) the specialist discovery and development pharmaceutical company is pleased to announce today the final results from a Phase IIb trial of LUPUZOR(TM) in active patients with Systemic Lupus Erythematosus (SLE). Lupuzor(TM) administered at 200 mcg once-a-month for 3 months plus standard of care achieved a clinically significant improvement in patient response rate as measured by the combined score compared to placebo plus standard of care. The study results also show that Lupuzor(TM) was generally well tolerated, with adverse event rates lower with Lupuzor(TM) when compared to placebo.
On the go?
Text INFO to 50555 and opt-in to receive breaking news about lupus on your mobile phone.
Message and Data Rates May Apply. Text STOP to 50555 to STOP. Text HELP to 50555 for HELP. Full Terms